Organon Korea releases first product after spinoff

targets postpartum hemorrhage market

First launch of a product that targets women's health since the launch of the Korean subsidiary

About 20% of mothers experience postpartum hemorrhage, targeting unmet demand and underserved markets

Conventional balloon dilation takes 12 to 24 hours... JADA’s median time to control bleeding is 3 minutes

Organon Korea is launching a new product for the first time since its spin-off in June 2019 and is beginning to expand its influence in earnest.

 

The product, which was unveiled about 3 years after the official launch of the Korean subsidiary, is JADA, a medical device used to control and treat postpartum hemorrhage.

 

The company plans to target the market with its women-focused strategy that differentiates itself from other companies.

 

At a media session held on the 19th, the company announced the launch of JADA and expressed Organon's commitment to improving women's health and safe birthing environments in this era of low fertility.

 

JADA is a new technology that has emerged 15 years after the previously used “intrauterine balloon tamponade and compression suture.” In the case of intrauterine balloon tamponade and compression, hemostasis was achieved by directly applying pressure to the inner wall of the uterus for 12 to 24 hours, but JADA induces physiologic contraction by creating a negative pressure in the uterus within a few minutes and applying pressure (up to 90 mmHg).

 

In the PEARLE trial, 94% of patients could control postpartum hemorrhage without additional treatment, and the median time taken to control their bleeding was 3 minutes.

 

In March of last year, JADA was approved by the Ministry of Food and Drug Safety to control and treat abnormal postpartum hemorrhage when conservative management of the uterus is required.

 

In June of the same year, intrauterine negative pressure hemostasis using JADA was listed as a new health technology based on the results of the safety and effectiveness evaluation of new health technologies by the National Evidence-based Healthcare Collaborating Agency (NECA).

 

Jada's indication, postpartum hemorrhage, is a condition with a high unmet need in women's health worldwide, and it is one of the complications of childbirth that occurs in one in six mothers worldwide, highlighting the need for immediate and appropriate treatment.

 

On this day, Professor Geum Joon Cho of the Department of Obstetrics and Gynecology at Korea University Guro Hospital explained, “One of the main causes of postpartum hemorrhage is uterine atony.

 

A normal uterus naturally stops bleeding through contraction after childbirth, but in the case of uterine atony, the contraction does not occur properly, so the bleeding continues.

 

If the bleeding is not controlled with initial treatment, an intrauterine device is inserted to try to stop the bleeding.” Professor Cho added, “In Korea, as of 2021, labor and delivery complications account for 34.8% of the causes of maternal mortality, and any postpartum hemorrhage that may occur in connection with this should be treated immediately.” He also emphasized, “For mothers experiencing postpartum hemorrhage, prompt judgment by on-site medical staff and the use of appropriate medical devices are very important.” Professor Cho explained that JADA is meaningful in that it provides a new treatment option that can quickly and accurately control postpartum hemorrhage, in the current situation where there is a high level of interest in maternal health due to the low birth rate issue.

 

Professor Cho said, “NECA has been evaluated as having an acceptable safety profile, a high treatment success rate, and an effectively low volume of transfused blood, so it is worth trying by clinicians.” Meanwhile, this launch is significant in that it marks the beginning of the company’s movement to specialize in solutions that are specifically designed for women's health, which has been a key focus of Organon Korea since its inception.

 

Jung Eun Jang, Country Medical Director at Organon Korea, said, “Since Organon was launched with the vision of promoting women's health, we have been continuously striving to provide a wider range of choices by providing various solutions to treat diseases that occur only in women or are disproportionately affected and have unique effects on women.” So Eun Kim, Managing Director of Organon Korea, added, “Postpartum hemorrhage is a problem that can affect not only the mother but also the unborn child, the family, and society as a whole.

 

We hope that the launch of this product will create an environment where postpartum hemorrhage can be treated more quickly and effectively.”